tiprankstipranks
Trending News
More News >
IDT Australia Limited (AU:IDT)
ASX:IDT
Australian Market

IDT Australia Limited (IDT) AI Stock Analysis

Compare
4 Followers

Top Page

AU

IDT Australia Limited

(Sydney:IDT)

Rating:44Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
IDT Australia Limited's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flow being the most critical issues. Technical analysis supports a neutral to slightly negative view, in line with the company's current financial state. The lack of a positive P/E and dividend yield further weighs on the stock's attractiveness.

IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)

IDT Australia Limited Business Overview & Revenue Model

Company DescriptionIDT Australia Limited (IDT) is a pharmaceutical manufacturing company based in Australia. It specializes in the development, production, and supply of high-quality pharmaceutical products. The company operates within the pharmaceutical sector, focusing on both proprietary and contract manufacturing services. IDT's core products and services include the production of active pharmaceutical ingredients (APIs) and finished dosage forms, as well as offering services related to clinical research and development.
How the Company Makes MoneyIDT Australia Limited generates revenue primarily through the manufacturing and supply of pharmaceutical products. The company's key revenue streams include sales of active pharmaceutical ingredients (APIs) and finished dosage forms to pharmaceutical companies. Additionally, IDT provides contract manufacturing services, which involve producing pharmaceutical products on behalf of other companies. This includes both proprietary products developed by IDT and products manufactured under contract for third-party clients. The company may also engage in partnerships and collaborations with other pharmaceutical entities to expand its market reach and product offerings. Revenue growth is influenced by factors such as demand for pharmaceuticals, regulatory approvals, and the company's ability to secure manufacturing contracts.

IDT Australia Limited Financial Statement Overview

Summary
IDT Australia Limited faces substantial financial hurdles, with persistent losses and negative cash flow. While revenue growth is a positive sign, the company needs to address operational inefficiencies and improve cash management. The low leverage provides some stability, but enhancing profitability is crucial for future growth.
Income Statement
45
Neutral
The income statement reveals a troubling trend in profitability. Despite revenue growth of 90.7% from 2023 to 2024, the company has consistently posted net losses, with a net profit margin of -40.9% in 2024. The gross profit margin improved to 50.7% in 2024, but negative EBIT and EBITDA margins suggest operational inefficiencies.
Balance Sheet
50
Neutral
The balance sheet shows a moderate level of risk. The debt-to-equity ratio is 0.19, indicating low leverage, which is positive. However, stockholders' equity has decreased over the years, and the equity ratio stands at 74.7%. The company's total assets have grown, but there's a need to improve equity growth to support long-term stability.
Cash Flow
40
Negative
Cash flow analysis indicates significant challenges. The free cash flow in 2024 was deeply negative, showing a decline from 2023. The operating cash flow to net income ratio is negative, highlighting cash flow generation issues relative to reported losses.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
18.77M13.23M6.93M12.11M15.99M14.10M
Gross Profit
10.01M10.42M-3.53M2.82M4.88M3.37M
EBIT
-3.73M-6.85M-9.78M-1.88M966.00K-1.28M
EBITDA
-4.43M-5.13M-8.85M-340.00K2.75M721.00K
Net Income Common Stockholders
-4.80M-5.41M-8.50M-1.16M2.10M-1.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.82M904.00K4.43M9.21M6.93M6.86M
Total Assets
39.45M31.37M28.29M30.08M34.13M28.59M
Total Debt
479.00K4.47M740.00K881.00K766.00K5.00K
Net Debt
-8.34M3.96M-3.69M-8.33M-6.16M-6.86M
Total Liabilities
7.59M7.93M4.15M3.46M6.51M5.29M
Stockholders Equity
31.85M23.44M24.14M26.63M27.61M23.30M
Cash FlowFree Cash Flow
-11.86M-10.30M-8.42M1.95M-156.00K-2.65M
Operating Cash Flow
-10.70M-9.60M-7.90M2.86M370.00K-1.89M
Investing Cash Flow
-1.16M-1.09M-522.00K-912.00K-526.00K-761.00K
Financing Cash Flow
8.76M6.77M3.64M337.00K224.00K12.00K

IDT Australia Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.10
Negative
100DMA
0.10
Negative
200DMA
0.11
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
46.08
Neutral
STOCH
20.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.08 is Neutral, neither overbought nor oversold. The STOCH value of 20.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCSL
69
Neutral
$117.14B28.1215.38%1.85%8.00%9.09%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
AUIDT
44
Neutral
AU$41.35M-19.31%72.25%43.66%
AURCE
43
Neutral
AU$79.91M
-33.01%
AUCYP
43
Neutral
AU$38.41M-75.39%44.29%
AUSPL
42
Neutral
AU$38.89M-43.63%-67.07%-47.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IDT
IDT Australia Limited
0.10
-0.02
-16.67%
AU:CSL
CSL
241.92
-40.08
-14.21%
AU:CYP
Cynata Therapeutics Limited
0.17
-0.16
-48.48%
AU:SPL
Starpharma Holdings Limited
0.09
>-0.01
-5.10%
AU:RCE
Recce Pharmaceuticals Ltd.
0.30
-0.22
-42.31%

IDT Australia Limited Corporate Events

IDT Australia Reports 30% Revenue Growth and Strong Contract Pipeline
Apr 29, 2025

IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.

IDT Australia Director Increases Stake in Company
Apr 14, 2025

IDT Australia Limited announced a change in the director’s interest in securities, with Geoffrey Sam acquiring additional ordinary fully paid shares through on-market trades. This acquisition increases his total holdings, potentially signaling confidence in the company’s future performance and stability, which may positively impact stakeholder perception.

IDT Australia Secures $3.2M Contract for NPI-001 Manufacturing
Apr 9, 2025

IDT Australia Limited has secured a five-year, $3.2 million contract with Nacuity Pharmaceuticals for the manufacture of NPI-001, an investigational treatment for retinitis pigmentosa. This contract involves recommissioning IDT’s 4,000L Active Pharmaceutical Ingredient plant, making it the largest small molecule API facility in Australia, which strategically positions IDT to address potential drug shortages and expand its manufacturing capabilities.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.